Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
NRSN stock price ended at $0 on 星期五, after dropping NaN%
On the latest trading day May 01, 2026, the stock price of NRSN fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for NRSN decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.